Amarillo Biosciences, Inc. announced this morning that clinical supplies were shipped to CytoPharm, Inc., its partner in Taiwan, for use in a study of 165 patients with chronic hepatitis C virus infection. The objective of this trial is to reduce the virologic relapse rate for those patients who have taken high dose injectable interferon alpha and Ribavirin.
The trial’s start date is anticipated to occur in the second quarter of this year and to be completed next year. The patients participating in the study will receive one of two different dosages of oral human interferon alpha or placebo daily for 24 weeks, then receive no treatment for 24 weeks to observe for relapse.
Today, there are approximately 170 million people chronically infected with hepatitis C virus worldwide. The incidence of cirrhosis in chronic hepatitis C patients is 10-20%, and 1-5% develop liver cancer. Most infections are transmitted by direct contact with blood through transfusions not screened for hepatitis C virus, inadequately sterilized needles and syringes, sexual and perinatal transmission. Currently there is no effective vaccine against hepatitis C virus.
In the press release, the company also announced that its Taiwanese partner will be testing oral interferon in human studies of chronic active hepatitis B and influenza.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment